Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?

BACKGROUND: The survival rates in population-based series of glioblastoma (GBM) differ substantially from those reported in clinical trials. This discrepancy may be attributed to that patients recruited to trials tend to be younger with better performance status. However, the proportion and characte...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaga, Erlend, Skretteberg, Marthe Andrea, Johannesen, Tom Børge, Brandal, Petter, Vik-Mo, Einar O, Helseth, Eirik, Langmoen, Iver A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914075/
https://www.ncbi.nlm.nih.gov/pubmed/33665615
http://dx.doi.org/10.1093/noajnl/vdab008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914075/
https://www.ncbi.nlm.nih.gov/pubmed/33665615
http://dx.doi.org/10.1093/noajnl/vdab008

Ejemplares similares